360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Humalog

Type: Product

Name: Humalog

First reported May 23 2013 - Updated May 23 2013 - 1 reports

MannKind Corp

The Coming Diabetes Wars

War is brewing in the multibillion-dollar diabetes market. In particular, a major skirmish will soon be fought over which insulin products will emerge as victors in a changing landscape. How are the battle lines taking shape? Here's a quick overview.The ... [Published Motley Fool - May 23 2013]

Entities: Insulin, MannKind Corp, Lantus, NovoRapid, NOVO NORDISK A/S

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Pfizer Inc

4 Big Drug Companies With Big Juicy Yields

David is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.Drug companies have been revenue generating machines for long. They’re in the enviable position of being able to profit ... [Published Motley Fool - May 22 2013]

Entities: Drugs, Pfizer Inc, Patent, Dividend Yield

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Ambiguous Orders Written by Prescribers

There has been much written about problems with handwritten orders for insulin, including the use of dangerous abbreviations or dose expressions and other shortcuts when communicating orders. How the use of the letter "U" to abbreviate "unit" has contributed ... [Published Diabetes in Control - May 21 2013]

Entities: Insulin, Lantus, Humalog, Physician

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Drug Patent Expirations in May 2013

Copyright © thinkBiotech Drug Patent Expirations for May 2013TradenameApplicantGeneric NamePatent NumberPatent Expiration HUMALOG PEN Lilly insulin lispro recombinant 5,514,646 May 7, 2013 GEMZAR Lilly gemcitabine hydrochloride 5,464,826*PED ... [Published Biotech Blog - May 13 2013]

Entities: Recombinant, Humalog, Insulin

First reported May 08 2013 - Updated May 08 2013 - 3 reports

Ranbaxy Laboratories Ltd

Indias top generic drugmakers look to US as patents end

:04 Posted by 3MUMBAI: India's top drugmakers, among the world's biggest producers of cheap generic medicines, are looking beyond their own shores to generate revenue, seeking to profit from big-selling drugs going off-patent this year in the lucrative ... [Published Business Recorder - May 08 2013]

Entities: Ranbaxy Laboratories Ltd, Patent, Drugs, India

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Johnson & Johnson

3 Bio Companies Facing The Patent Cliff

Patent cliff is a colloquialism for the sharp decline in company revenue due to patent expiry of their one or more leading products, This article looks at three major biotech companies facing significant revenue loss in 2013 due to patent expiration - ... [Published Seeking Alpha - May 07 2013]

Entities: Patent, Drugs, Multiple Sclerosis, Johnson & Johnson, Eli Lilly & Company

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Drug Patent Expirations for May 7 2013

Copyright © thinkBiotech If your reader cannot render the information below, go tohttp://www.DrugPatentWatch.com/innovation to see the latest expirationsbody { font-family:Calibri, tahoma, arial,sans-serif;}table { font-size:12px; font-family:Calibri, ... [Published Biotech Blog - May 07 2013]

Entities: Recombinant, Patent, Humalog, Insulin

First reported Apr 26 2013 - Updated Apr 26 2013 - 1 reports

Partially Disposable Insulin Pump Hits the Market

The Asante Snap, a new style of partially disposable insulin pump, has hit the market in certain states in the Northeast and will be available throughout the United States later this year.Manufacturer Asante received clearance from the US Food and Drug ... [Published Diabetes Self-Management - Apr 26 2013]

Entities: Insulin, Market, Infusion, Humalog

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Lilly's first-quarter income up 3%

Eli Lilly has turned in a profit for the first quarter of the year, as cost-cutting measures helped offset a greater investment in R&D. The US drug giant posted operating income of $1.422 billion (reported), marking a rise of 3% over the year-ago quarter, ... [Published Pharma Times - Apr 25 2013]

Entities: Zyprexa, Eli Lilly & Company, Cymbalta

First reported Apr 17 2013 - Updated Apr 17 2013 - 1 reports

Lilly's diabetes drug dulaglutide shines again in Phase III

Eli Lilly has presented more promising late-stage data on its investigational long-acting diabetes drug dulaglutide.The US major has presented top-line results from two Phase III studies from the five-trial AWARD programme. The first showed that dulaglutide ... [Published Pharma Times - Apr 17 2013]

Entities: Dulaglutide, Phase III, Eli Lilly & Company

First reported Apr 16 2013 - Updated Apr 16 2013 - 1 reports

Investor Watch List: Week of April 15 2013

For investors with the time, money and fortitude to tackle the world of individual investments in stocks of their own personal choosing, the task can at times seem formidable with a limitless supply of possibilities. For the week ahead, I wish to help ... [Published Seeking Alpha - Apr 16 2013]

Entities: Biodel Inc, Humalog, Polymer, Eteplirsen, Watch List

First reported Feb 12 2013 - Updated Feb 12 2013 - 1 reports

Which Patents Cover the Most Drugs

Copyright © thinkBiotech This is a fun infographic. Rather than asking which drugs have the most patents, this chart shows the patents which cover the most drugs. The patents covering the most drugs are: Patent: 5,605,674 PROAIR+HFA PROVENTIL-HFA ... [Published Biotech Blog - Feb 12 2013]

Entities: Humalog, Flovent Diskus, Stalevo, Advair Diskus, Patent

Quotes

...for generic drugmakers to sell their cheaper copies of patented drugs at home, the likes of Ranbaxy still see the US market as being more lucrative. "Ranbaxy's domestic business generates only 25 percent of sales and the path ahead looks tough as growth has slowed down due to pricing pressures and intense competition" said Deepak Malik, a pharmaceuticals analyst at Emkay Global in Mumbai

Indias top generic drugmakers look to US as patents end [Published Business Recorder - May 08 2013]

Mylan CEO Heather Bresch commented, "This collaboration builds off of our existing successful partnership for generic biologics with Biocon and brings Mylan a portfolio of high-value insulin analog products. This collaboration further expands and diversifies our pipeline of complex, difficult-to-manufacture products with strong future growth potential. Importantly, we believe we have the opportunity to be one of the first generic entrants in developed markets into the rapidly growing diabetes area, helping to address unmet needs and reduce the economic burden to those battling the disease and to the global healthcare system."

Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products [Published AndhraNews.net - May 04 2013]

"We have such a robust pipeline that we expect to have the broadest portfolio in our industry. With our late-stage development, we are present across the continuum" Enrique Conterno, the head of Lilly's diabetes business, told Reuters in an interview

Lilly broadens diabetes offer with eye on bigger slice of booming market [Published Reuters - May 03 2013]

...yen and a slowdown in parts of our animal health business," commented John Lechleiter, company chairman president and chiefchief executive. "Most importantly, we have remained focused on advancing our late-stage pipeline, and are pleased to announce that we have received Fast Track designation from the FDA and have initiated a rolling submission for ramucirumab" he added

Lilly's first-quarter income up 3% [Published Pharma Times - Apr 25 2013]

More Content

sort by: Date \| Relevance
The Coming Diabetes Wars [Published Motley Fool - May 23 2013]
4 Big Drug Companies With Big Juicy Yields [Published Motley Fool - May 22 2013]
New Routes in Drug Delivery [Published Pharmaceutical & Medical Packaging News - May 21 2013]
Ambiguous Orders Written by Prescribers [Published Diabetes in Control - May 21 2013]
MannKind Corporation (MNKD): Why Have Shares Mo... [Published InsiderMonkey.com - May 19 2013]
Diabetes drugs market will reach $55.3bn in 201... [Published Prlog - May 16 2013]
Drug Patent Expirations in May 2013 [Published Biotech Blog - May 13 2013]
Global biosimilars market to reach $2.45bn in 2013 [Published PMLive - May 10 2013]
MannKind Corporation's CEO Discusses Q1 2013 Re... [Published Seeking Alpha - May 10 2013]
Indias top generic drugmakers look to US as pat... [Published Business Recorder - May 08 2013]
Top generic drugmakers look to US as patents end [Published Yahoo! UK and Ireland - May 08 2013]
UPDATE 1-India's top generic drugmakers look to... [Published Reuters - May 08 2013]
3 Bio Companies Facing The Patent Cliff [Published Seeking Alpha - May 07 2013]
Drug Patent Expirations for May 7 2013 [Published Biotech Blog - May 07 2013]
Mylan Enhances Partnership with Biocon through ... [Published AndhraNews.net - May 04 2013]
Lilly broadens diabetes offer with eye on bigge... [Published Reuters - May 03 2013]
Committee for Free Expression Director Héctor B... [Published Hondurasweekly - Apr 29 2013]
Police Strike in Honduras [Published Hondurasweekly - Apr 29 2013]
Massive Cocaine Bust in Venezuela Highlights Sc... [Published Hondurasweekly - Apr 29 2013]
JTF-Bravo and Honduran Police Inspire Tomorrow’... [Published Hondurasweekly - Apr 29 2013]
Partially Disposable Insulin Pump Hits the Market [Published Diabetes Self-Management - Apr 26 2013]
Lilly's first-quarter income up 3% [Published Pharma Times - Apr 25 2013]
Clean Superiority Sweep For Dulaglutide Could R... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 17 2013]
Lilly diabetes drug dulaglutide meets late-stag... [Published Diabetes.co.uk - Apr 17 2013]
Lilly's diabetes drug dulaglutide shines again ... [Published Pharma Times - Apr 17 2013]
Weekly GLP-1 Works as Well as Insulin, Lilly Says [Published MedPage Today - Apr 16 2013]
Investor Watch List: Week of April 15 2013 [Published Seeking Alpha - Apr 16 2013]
LifeSci Advisors Initiates Coverage of Adocia [Published Marketwire - Breaking News Releases - Apr 03 2013]
Analysts: Baidu’s Growth is Declining and 4 New... [Published Wall St. Cheat Sheet - Mar 28 2013]
Biodel Completes Enrollment in Phase 2 Clinical... [Published GlobeNewswire: Advertising News - Mar 28 2013]

Blogs

sort by: Date \| Relevance
Drug Patent Expirations in May 2013 [Published Biotech Blog - May 13 2013] Copyright © thinkBiotech Drug Patent Expirations for May 2013TradenameApplicantGeneric NamePatent NumberPatent Expiration HUMALOG PEN Lilly insulin lispro recombinant 5,514,646 May 7, 2013 GEMZAR Lilly gemcitabine hydrochloride 5,464,826*PED ...
Drug Patent Expirations for May 7 2013 [Published Biotech Blog - May 07 2013] Copyright © thinkBiotech If your reader cannot render the information below, go tohttp://www.DrugPatentWatch.com/innovation to see the latest expirationsbody { font-family:Calibri, tahoma, arial,sans-serif;}table { font-size:12px; font-family:Calibri, ...
Analysts: Baidu’s Growth is Declining and 4 New... [Published Wall St. Cheat Sheet - Mar 28 2013] Biogen Idec Inc. ( NASDAQ:BIIB ): Stifel decided to raise the company’s price target due to its belief that the label assigned by the FDA to the company’s MS drug, Tecfidera, was more favorable than expected. The firm is convinced that the label de-risks ...
Deals Of The Week Notes Bayer's Partnerships Ar... [Published The IN VIVO Blog - Feb 15 2013] Bayer Healthcare’s pharmaceuticals division has certainly had its ups and downs, and some ultra-tense relationships with partners—notably the very public lawsuit Onyx Pharmaceuticals filed against it, which the partners settled in October 2011. ...
Which Patents Cover the Most Drugs [Published Biotech Blog - Feb 12 2013] Copyright © thinkBiotech This is a fun infographic. Rather than asking which drugs have the most patents, this chart shows the patents which cover the most drugs. The patents covering the most drugs are: Patent: 5,605,674 PROAIR+HFA PROVENTIL-HFA ...

Press Releases

sort by: Date \| Relevance
LifeSci Advisors Initiates Coverage of Adocia [Published Marketwire - Breaking News Releases - Apr 03 2013]
Biodel Completes Enrollment in Phase 2 Clinical... [Published GlobeNewswire: Advertising News - Mar 28 2013]
Biodel Reports Positive Top-Line Results From C... [Published GlobeNewswire: Acquisitions News - Jan 24 2013]